RecruitingPHASE1, PHASE2NCT03465592

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal Investigator
Nicolas Llosa, MD
Johns Hopkins University
Intervention
Nivolumab(drug)
Enrollment
39 target
Eligibility
40 years · All sexes
Timeline
20182029

Study locations (4)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03465592 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma

← Back to all trials